Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately [Yahoo! Finance]
Summit Therapeutics (NASDAQ:SMMT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)